DGX stock: buy or sell?
August 23rd, 2019
Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally.
Should I buy DGX stock?Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. Having a trading strategy helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
None of our preferred buy setups matches with Quest Diagnostics stock situation right now, therefore this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Quest Diagnostics stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we detected 15 ratings published for DGX stock in the last month.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-7-24||JPMorgan Chase & Co.||n/a||Neutral|
|2019-7-24||Credit Suisse Group||n/a||Neutral|
|2019-7-15||Goldman Sachs Group||Neutral||Sell|
|2019-4-2||Jefferies Financial Group||Hold||Buy|
|2019-3-18||Credit Suisse Group||Outperform||Neutral|
|2019-2-19||Credit Suisse Group||Outperform||Outperform|
DGX stock analysis
Shares of Quest Diagnostics ended today at $101.60 and slightly fell a lame -0.99%.
Shares of Quest Diagnostics closed today at $101.60 and slightly fell a lame -0.99%. Since June when SMA100d and SMA200d crossed up, DGX price gained $1.09 per share (1.08%). DGX is soaring again after a 2.90% correction from its last top on August 13th at $102.19. Since price and SMA200d lines crossed up on April, DGX climbed $7.84 (8.36%).
Shares of Quest Diagnostics stepped up a slightly good 0.99% this week.
DGX shows a long term strength with several rising tops and rising bottoms. It left a new bottom at $96.94 early August. Previous top ($104.90) will play as a resistance in possible new gains. Since mid June when SMA20w and SMA40w crossed up, DGX price gained $2.77 per share (2.80%). Since price and SMA40w lines crossed up late April, DGX climbed $16.29 (19.10%).
DGX stock price history
DGX stock went public on December 17th, 1996 with a price of $2.981. Since then, DGX stock surged a 3,309.40%, with a yearly average of 150.40%. If you had invested $1,000 in DGX stock in 1996, it would worth $33,094.00 today.
1: Adjusted price after possible price splits or reverse-splits.
DGX stock historical price chart
DGX stock reached 52-week highs at $108.56, and all-time highs 2018-06-25 with a price of 112.74.
DGX stock price target is $104.90How much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. We have 13 price targets for Quest Diagnostics stock released in the last month:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-8-23||Morgan Stanley||Raises Target||$111.00||$121.00||9%|
|2019-7-24||Morgan Stanley||Raises Target||$104.00||$111.00||6.7%|
|2019-7-24||JPMorgan Chase & Co.||Raises Target||$100.00||$111.00||11%|
|2019-7-24||Credit Suisse Group||Reiterates||$99.00||$105.00||6.1%|
|2019-7-24||Canaccord Genuity||Raises Target||$108.00||$112.00||3.7%|
|2019-7-15||Goldman Sachs Group||Downgrades||$90.00||$85.00||-5.6%|
|2019-4-25||Morgan Stanley||Raises Target||$98.00||$104.00||6.1%|
|2019-4-24||UBS Group||Raises Target||$91.00||$99.00||8.8%|
|2019-3-18||Credit Suisse Group||Downgrades||n/a||$91.00||-|
|2019-2-19||Credit Suisse Group||Lowers Target||$103.00||$101.00||-1.9%|
Financials and fundamental analysis
Earnings date and Earnings per ShareOn February, Quest Diagnostics presented its financial report, in line with analysts' consensus and posted a $1.36 Earnings per Share. Unfortunately, reported EPS is not yet available in our database.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Quest Diagnostics annual turnover grew a tiny 1.74% to $7,531.00 million USD from $7,402.00 marked in 2017. When comparing 2018 vs 2017, however, profit margin (that is, the net income divided by revenues) remained constant a -0.66% to 9.77%.
|2013||$7,150 M||-||$811 M11.3%||-|
|2014||$7,435 M||3.99%||$556 M7.5%||-31.44%|
|2015||$7,493 M||0.78%||$709 M9.5%||27.52%|
|2016||$7,515 M||0.29%||$645 M8.6%||-9.03%|
|2017||$7,402 M||-1.50%||$772 M10.4%||19.69%|
|2018||$7,531 M||1.74%||$736 M9.8%||-4.66%|
Quarterly financial resultsQuest Diagnostics posted $1,839.00 M in sales for 2018-Q4, a -2.65% less compared to previous quarter. Reported quarter income marked $127.00 M with a profit margin of 6.91%. Profit margin depreciated a -4.37% compared to previous quarter when profit margin was 11.28%. When comparing revenues to same quarter last year, Quest Diagnostics sales marked a frightening slide and plummed a -15.33%. Looking back to recent quarterly results, Quest Diagnostics posted 2 positive quarters in a row.
|2017-Q2||$1,940 M||-||$193 M9.9%||-|
|2017-Q3||$1,930 M||-0.52%||$160 M8.3%||-17.10%|
|2017-Q4||$2,172 M||12.54%||$254 M11.7%||58.75%|
|2018-Q1||$1,884 M||-13.26%||$177 M9.4%||-30.31%|
|2018-Q2||$1,919 M||1.86%||$219 M11.4%||23.73%|
|2018-Q3||$1,889 M||-1.56%||$213 M11.3%||-2.74%|
|2018-Q4||$1,839 M||-2.65%||$127 M6.9%||-40.38%|
|2019-Q1||$1,891 M||2.83%||$164 M8.7%||29.13%|
Quest Diagnostics ownershipWhen you are planning to buy a stock, it's worth to check its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Quest Diagnostics, 0.35% of all outstanding shares are owned by its staff.
Bearish positions for DGX stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Quest Diagnostics:
|Market cap||$13.7 B||$148.3 M||$2.7 B||$16.3 B||$2.3 B|
|Total shares||134.6 M||47.2 M||37.1 M||98.5 M||95.3 M|
|Float shares||134.0 M||35.2 M||25.0 M||97.1 M||94.8 M|
|- Institutional holdings (%)||91.5%||75.8%||86.9%||94.1%||77.2%|
|- Insider holdings (%)||0.4%||7.4%||2.8%||0.6%||8.1%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Friday, August 23rd, 2019|
|Day range||$101.23 - $103.67|
|Average true range||$1.72|
|50d mov avg||$101.25|
|100d mov avg||$97.99|
|200d mov avg||$92.24|
Quest Diagnostics performanceTo better understand Quest Diagnostics performance you must compare its gains with other related stocks in same sector or industry. In the following table, we compare Quest Diagnostics performance to Enzo Biochem, Genomic Health, Laboratory Corporation of America, NeoGenomics, Psychemedics and Qiagen:
Quest Diagnostics competitorsWe selected a few stocks to conform a list of Quest Diagnostics competitors to check if you are interested in investing in DGX:
- Enzo Biochem (ENZ)
- Genomic Health (GHDX)
- Laboratory Corporation of America (LH)
- NeoGenomics (NEO)
- Psychemedics (PMD)
- Qiagen (QGEN)
Latest DGX stock news
- Seeking AlphaDiagnosing Quest DiagnosticsMarch 15, 2019